Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Histone deacetylases: unique players in shaping the epigenetic histone code.

Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF.

Ann N Y Acad Sci. 2003 Mar;983:84-100. Review.

PMID:
12724214
2.

Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.

Hadnagy A, Beaulieu R, Balicki D.

Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284. Review.

3.

Rational development of histone deacetylase inhibitors as anticancer agents: a review.

Acharya MR, Sparreboom A, Venitz J, Figg WD.

Mol Pharmacol. 2005 Oct;68(4):917-32. Epub 2005 Jun 14. Review.

4.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
5.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

6.

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE.

Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. Review.

PMID:
17896917
7.

From discovery to the coming generation of histone deacetylase inhibitors.

Yoshida M, Matsuyama A, Komatsu Y, Nishino N.

Curr Med Chem. 2003 Nov;10(22):2351-8. Review.

PMID:
14529478
8.

NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.

Vaquero A, Sternglanz R, Reinberg D.

Oncogene. 2007 Aug 13;26(37):5505-20. Review.

PMID:
17694090
9.

CpG island methylation and histone modifications: biology and clinical significance.

Esteller M.

Ernst Schering Res Found Workshop. 2006;(57):115-26. Review.

PMID:
16568952
10.

Role of histone deacetylase inhibitors in the treatment of cancer (Review).

Mei S, Ho AD, Mahlknecht U.

Int J Oncol. 2004 Dec;25(6):1509-19. Review.

PMID:
15547685
11.

Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition.

Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES.

Mol Cell Biol. 2003 Nov;23(21):7719-31.

12.

Histone deacetylase inhibitors: molecular mechanisms of action.

Xu WS, Parmigiani RB, Marks PA.

Oncogene. 2007 Aug 13;26(37):5541-52. Review.

PMID:
17694093
13.

The structure and function of histone deacetylases: the target for anti-cancer therapy.

Zhang Y, Fang H, Jiao J, Xu W.

Curr Med Chem. 2008;15(27):2840-9. Review.

PMID:
18991639
14.

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.

Yoshida M, Shimazu T, Matsuyama A.

Prog Cell Cycle Res. 2003;5:269-78. Review.

PMID:
14593721
15.

Epigenetic regulation of airway inflammation.

Adcock IM, Tsaprouni L, Bhavsar P, Ito K.

Curr Opin Immunol. 2007 Dec;19(6):694-700. Epub 2007 Aug 27. Review.

PMID:
17720468
16.

HDAC inhibitors for the treatment of cancer.

Secrist JP, Zhou X, Richon VM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Review.

PMID:
14763127
17.
18.

Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.

Weidle UH, Grossmann A.

Anticancer Res. 2000 May-Jun;20(3A):1471-85. Review.

PMID:
10928059
19.

Prospects: histone deacetylase inhibitors.

Dokmanovic M, Marks PA.

J Cell Biochem. 2005 Oct 1;96(2):293-304. Review.

PMID:
16088937
20.

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.

Gallinari P, Di Marco S, Jones P, Pallaoro M, Steink├╝hler C.

Cell Res. 2007 Mar;17(3):195-211. Review.

Supplemental Content

Support Center